|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MYCL |
Gene summary for MYCL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MYCL | Gene ID | 4610 |
| Gene name | MYCL proto-oncogene, bHLH transcription factor | |
| Gene Alias | L-Myc | |
| Cytomap | 1p34.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P12524 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4610 | MYCL | LZE2T | Human | Esophagus | ESCC | 2.18e-04 | 5.91e-01 | 0.082 |
| 4610 | MYCL | LZE7T | Human | Esophagus | ESCC | 3.98e-06 | 2.50e-01 | 0.0667 |
| 4610 | MYCL | LZE20T | Human | Esophagus | ESCC | 4.88e-05 | 1.48e-01 | 0.0662 |
| 4610 | MYCL | LZE22T | Human | Esophagus | ESCC | 1.57e-02 | 2.64e-01 | 0.068 |
| 4610 | MYCL | LZE24T | Human | Esophagus | ESCC | 2.54e-14 | 8.04e-01 | 0.0596 |
| 4610 | MYCL | LZE21T | Human | Esophagus | ESCC | 8.02e-04 | 2.61e-01 | 0.0655 |
| 4610 | MYCL | P1T-E | Human | Esophagus | ESCC | 1.09e-04 | 2.61e-01 | 0.0875 |
| 4610 | MYCL | P4T-E | Human | Esophagus | ESCC | 1.26e-16 | 5.18e-01 | 0.1323 |
| 4610 | MYCL | P8T-E | Human | Esophagus | ESCC | 1.54e-05 | 2.10e-01 | 0.0889 |
| 4610 | MYCL | P9T-E | Human | Esophagus | ESCC | 1.65e-09 | 2.62e-01 | 0.1131 |
| 4610 | MYCL | P10T-E | Human | Esophagus | ESCC | 1.48e-104 | 1.88e+00 | 0.116 |
| 4610 | MYCL | P12T-E | Human | Esophagus | ESCC | 8.01e-22 | 5.22e-01 | 0.1122 |
| 4610 | MYCL | P15T-E | Human | Esophagus | ESCC | 5.96e-31 | 6.46e-01 | 0.1149 |
| 4610 | MYCL | P20T-E | Human | Esophagus | ESCC | 8.99e-31 | 5.87e-01 | 0.1124 |
| 4610 | MYCL | P21T-E | Human | Esophagus | ESCC | 3.09e-05 | 1.64e-01 | 0.1617 |
| 4610 | MYCL | P22T-E | Human | Esophagus | ESCC | 8.58e-07 | 2.83e-01 | 0.1236 |
| 4610 | MYCL | P23T-E | Human | Esophagus | ESCC | 7.44e-12 | 3.53e-01 | 0.108 |
| 4610 | MYCL | P26T-E | Human | Esophagus | ESCC | 2.03e-09 | 2.36e-01 | 0.1276 |
| 4610 | MYCL | P27T-E | Human | Esophagus | ESCC | 2.24e-21 | 5.82e-01 | 0.1055 |
| 4610 | MYCL | P28T-E | Human | Esophagus | ESCC | 9.82e-40 | 8.97e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
| GO:000991310 | Esophagus | ESCC | epidermal cell differentiation | 122/8552 | 202/18723 | 1.69e-05 | 1.51e-04 | 122 |
| GO:00456826 | Esophagus | ESCC | regulation of epidermis development | 46/8552 | 65/18723 | 3.65e-05 | 2.97e-04 | 46 |
| GO:00456046 | Esophagus | ESCC | regulation of epidermal cell differentiation | 41/8552 | 58/18723 | 1.00e-04 | 7.10e-04 | 41 |
| GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
| GO:00099139 | Oral cavity | OSCC | epidermal cell differentiation | 109/7305 | 202/18723 | 1.08e-05 | 1.14e-04 | 109 |
| GO:00456825 | Oral cavity | OSCC | regulation of epidermis development | 41/7305 | 65/18723 | 7.29e-05 | 5.73e-04 | 41 |
| GO:00456045 | Oral cavity | OSCC | regulation of epidermal cell differentiation | 36/7305 | 58/18723 | 3.15e-04 | 1.96e-03 | 36 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MYCL | SNV | Missense_Mutation | rs768216635 | c.998N>T | p.Ala333Val | p.A333V | P12524 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-BH-A0HB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| MYCL | insertion | Frame_Shift_Ins | novel | c.607_608insCAGACTTGATCAACATTGACCAT | p.Val203AlafsTer9 | p.V203Afs*9 | P12524 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| MYCL | SNV | Missense_Mutation | novel | c.478N>A | p.Asp160Asn | p.D160N | P12524 | protein_coding | tolerated(0.13) | possibly_damaging(0.839) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| MYCL | SNV | Missense_Mutation | novel | c.1062N>A | p.Ser354Arg | p.S354R | P12524 | protein_coding | deleterious(0.01) | benign(0.125) | TCGA-C5-A901-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MYCL | SNV | Missense_Mutation | novel | c.584N>T | p.Ser195Leu | p.S195L | P12524 | protein_coding | tolerated(0.06) | benign(0.062) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MYCL | SNV | Missense_Mutation | rs748297163 | c.962G>A | p.Arg321His | p.R321H | P12524 | protein_coding | deleterious(0) | possibly_damaging(0.63) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MYCL | SNV | Missense_Mutation | novel | c.695N>G | p.His232Arg | p.H232R | P12524 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AA-A01I-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MYCL | SNV | Missense_Mutation | novel | c.862N>T | p.Pro288Ser | p.P288S | P12524 | protein_coding | tolerated(0.22) | possibly_damaging(0.471) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
| MYCL | SNV | Missense_Mutation | novel | c.823G>A | p.Glu275Lys | p.E275K | P12524 | protein_coding | tolerated(0.47) | possibly_damaging(0.709) | TCGA-AA-A024-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MYCL | SNV | Missense_Mutation | c.397N>C | p.Glu133Gln | p.E133Q | P12524 | protein_coding | tolerated(0.35) | probably_damaging(0.99) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |